In Digital Health, the Payer Contract Is the Product

Two companies with near-identical clinical products can have completely different businesses, and the difference is almost never the software. It is the four or five clauses that determine how money moves.

Founders who came from consumer or enterprise SaaS consistently underestimate this. In most industries, the contract documents the business model. In healthcare, the contract is the business model.

The four structures, and what each one really means

Per member per month across an eligible population. You are paid for every member who could use the service, whether they do or not. This is the most attractive structure in the sector and the hardest to win. It gives predictable revenue, it decouples cost from engagement, and it makes your gross margin a function of how efficiently you deliver care to the fraction who actually enrol. The buyer will push back by demanding engagement guarantees, and the negotiation is really about where the engagement risk sits.

Per engaged member per month. You are paid only for members who meet an activity definition. This looks fair and it is operationally brutal. Your revenue now depends on a definition negotiated in a contract, your marketing spend becomes a cost of revenue, and the buyer has every incentive to tighten the definition at renewal. Read that definition with a lawyer and model it at half the engagement you expect.

Case rate or episode fee. You are paid a fixed amount for completing a defined episode. Clean, but it turns your business into an operations problem: your margin is entirely a function of cost to serve, and any clinical complexity you did not price for comes out of your gross margin.

Fee schedule billing. You bill existing codes. The advantage is that the payment infrastructure already exists and you do not need a contract negotiation to get paid. The disadvantage is that you are now exposed to coverage policy, prior authorization, documentation requirements and denial management, which means you need a revenue cycle function long before you can afford one.

At-risk and shared savings. You are paid a share of the savings you generate, or you accept downside. This is where the sector's rhetoric lives and where its cash flow dies. Savings must be measured against a counterfactual, which is a negotiated construct rather than a fact, and settlement typically occurs a year or more after the work. Founders sign these because they signal confidence. Then they discover that the attribution methodology, not their clinical results, determines whether they get paid.

The clauses that decide your enterprise value

Beyond the headline structure, five terms drive valuation more than most cap tables recognise.

Term and termination. A one-year contract terminable for convenience with sixty days' notice is not recurring revenue, whatever your board deck calls it. Multi-year with a fixed minimum is a different asset class entirely.

Attribution. Who counts as your member, when do they attach, when do they detach, and what happens when they change plans mid-year. In risk arrangements this single definition can swing economics by a wide margin.

The measurement counterfactual. Against what baseline is your effect measured, over what period, adjusted how. Ask for the exact methodology in writing before signing. If the payer will not commit to it, the savings clause is decorative.

Data rights. What claims and clinical data you receive, at what latency, and in what form. A savings contract without timely claims access is a contract you cannot manage. It is also, separately, the raw material for every product improvement you will make.

Most favoured nation and benchmarking clauses. These quietly cap your pricing across the entire book once one large customer signs.

What this means for how you build

Three practical consequences.

Hire contracting expertise absurdly early. The single highest-leverage hire in a payer-facing digital health company between seed and Series A is someone who has sat on the other side of these negotiations. They will not build product. They will double the value of everything you do build.

Choose the structure that matches your actual cost curve. If your cost to serve is dominated by clinician labour, at-risk contracts are dangerous, because your costs scale with utilisation while your revenue does not. If your cost to serve is mostly fixed technology, PMPM is a compounding machine.

Price the pilot as a term sheet. The economics you accept in a pilot become the benchmark for the enterprise agreement and, through benchmarking clauses, for every subsequent customer. There is no such thing as a temporary price in this industry.

The clinical evidence gets you the meeting. The contract structure determines whether the meeting was worth having.